Kornimate/medical-research-clean huggingface dataset:
neurodynamic intervention for lumbar radiculopathy

Conditions: Lumbar Radiculopathy

Summary: low back pain (lbp) is a common condition and has a significant impact on the individual in terms of pain and disability. lumbar radiculopathy occurs often with lbp and may be the result of a lumbar herniated disc which will irritate a lumbar nerve trunk resulting in intraneural inflammation. there is evidence supporting the use of manual therapies of lumbar radiculopathy. one potential manual therapy is neurodynamic mobilization technique. no scientific evidence, based on a rct, exists that this particular approach is beneficial for individuals with lbp and lumbar radiculopathy


Eligibility criteria:
inclusion criteria: * subjects with a confirmed (via mri) disc herniation at between l4 and s1 level; * subjects exhibiting lumbar radiating pain in the lower extremity for at least 3 months * subjects with a positive straight leg raise with symptoms reproduction exclusion criteria: * indication for surgical intervention; * had a confirmed disc herniation at other lumbar levels; * have had any other spinal conditions such as spinal tumors or spondylolisthesis; * had received treatment for this condition by a physical therapist the previous 6 month; * pregnancy
an assessment of the prevalence of spatial neglect in stroke survivors with aphasia

Conditions: Spatial Neglect; Aphasia; Stroke

Summary: the purpose of this study is to determine if stroke survivors with aphasia have spatial neglect (phase 1). if they are determined to have the condition phase 2 will be offered: which is prism adaptation treatment. this is a pilot study that will be performed with 4-5 subjects.

spatial neglect is a disorder that may occur after a brain injury such as stroke. spatial neglect may affect stroke recovery. one example of this heterogeneous condition: individuals with spatial neglect often pay more attention to one side of what they are looking at, even though they have no difficulty seeing. the study investigators would like to screen stroke survivors with aphasia because they may also have spatial neglect (right neglect after left hemisphere stroke), which is said by the literature to occur in 25% of cases. if it is identified, a treatment approach will be offered, to attempt to remediate the condition using prism goggles, following a prism treatment protocol based on previous studies.

Eligibility criteria:
inclusion criteria: * a stroke survivor with aphasia who is a member at the adler aphasia center exclusion criteria: * has a history of brain tumor, head injury with loss of consciousness, dementia, alzheimers

Keywords: spatial neglect aphasia
adaptation of high activity arthroplasty score to turkish

Conditions: Arthropathy; Surgery--Complications; Physical Disability

Summary: the objectives of this study were the translation, cross-cultural adaptation, and assessment of the psychometric properties of the turkish high-activity arthroplasty score (haas) in patients with primary tka.

the purpose of this study is to translate and cross-culturally adapt the haas instrument into turkish and investigate its psychometric properties. for cross-cultural adaptation, two bi-lingual translators used the back-translation procedure. within a 5-to-7-day period after the first assessment, the participants will complete the turkish version of haas to evaluate test-retest reliability. cronbach's alpha (α) will use to assess internal consistency. the correlations with the turkish version of the koos, sf-36 and fjs-12 will determine to check the validity.

Eligibility criteria:
inclusion criteria: 1. primary tha/tka due to primary osteoarthritis for \>6 months, 2. age \<65 3. to be able to communicate in turkish 4. agree to participate in the study exclusion criteria: 1. who do not agree to participate in the study 2- who will undergo 2nd revision tka 3- who have undergone lower extremity surgery and thus have sequelae 4-having cognitive impairment
periodontal regeneration versus tooth extraction and replacement denture in teeth with periodontal hopeless prognosis

Conditions: Periodontitis Complex

Summary: periodontal regeneration can change tooth prognosis and represents an alternative to extraction in teeth compromised by severe intrabony defects. the aim of this study is to compare periodontal regeneration (pr) with tooth extraction and replacement (ter) in a population with attachment loss to or beyond the apex of the root in terms of professional, patient reported and economic outcomes.

this was a single center 10-year randomized controlled clinical trial. 50 stage iii or iv periodontitis subjects with a severely compromised tooth with attachment loss to or beyond the apex were randomized to pr or ter with either an implant or a tooth supported fixed partial denture. subjects were kept on a strict periodontal supportive care regimen every 3 months and examined yearly. survival, complication free survival, recurrence analysis, oral health related quality of life and patient reported outcomes analyses will be performed.

Eligibility criteria:
inclusion criteria: * good general health * non-smokers or smokers with less than 20/day * good oral hygiene (fmps\<25%) * good control of periodontitis (fmbs\<25%) * good compliance with treatment * presence of generalised stage iii or iv periodontitis * radiographic bone loss to the apex or beyond the apex of the root at at least one interdental aspect * presence of severe clinical attachment level loss (\>10 mm) * presence of clearly identifiable crest of bone in adjacent teeth * lack of function due to hyper mobility * vital or non-vital teeth exclusion criteria: * medical contraindication to elective surgery * poor oral hygiene * incomplete control of periodontitis in the dentition * inadequate compliance * inability to provide informed consent

Keywords: periodontitis periodontal regeneration tooth extraction dental implant fixed partial denture survival analysis complication free survival recurrence analysis oral health related quality of life
aneurysm wall histology registry

Conditions: Brain Aneurysm

Summary: the purpose of this prospective registry is to determine if patients harboring intracranial aneurysms have any predictive markers between aneurysm wall tissue, cerebrospinal fluid and blood plasma.

to design a registry to evaluate the wall of intracranial aneurysms during open surgical clipping by direct photographic appearance, wall biopsy samples, csf and blood plasma fluid collection (interleukins; il-8/ matrix metalloproteinase; mmp-9) for complete evaluation and comparison. the focus of the registry will be to determine the presence of aneurysmal wall defects, mural clot, atherosclerotic and atheroma, wall permeability and delamination. these findings will then be correlated to the collected csf and blood values to determine if there is any direct features of the aneurysm wall that would predict any of the reported post embolic syndromes. the collected data can also be correlated to the peroperative imaging, (mri, ct and angiogram).

Eligibility criteria:
inclusion criteria: * patient \> 18 years but \< 80 years of age * patient with an unruptured intracranial aneurysm 8mm or larger * patient that surgical exposure and clipping will be the primary treatment option exclusion criteria: * any patient that has a ruptured intracranial aneurysm * any pediatric patients * any patient presenting with any pre-treatment intracranial lesions * vascular malformations * hemorrhage * normal pressure hydrocephalus * obstructive hydrocephalus * white matter disease * tumors * trauma * other vascular type lesions * any meningitis type symptoms * medical or surgical co-morbidities such that the patient's life expectancy is less than 1 year * inability to obtain consent
evaluation of wear experience with one week reusable contact lenses in habitual two week reusable lens wearers

Conditions: Myopia

Summary: this open-label study is of current acuvue® oasys® wearers (2 - week replacement, reusable lenses) who are satisfied with their current lenses. subjects will be refit into one week reusable contact lenses and will wear lenses for approximately 2 weeks. subjects will return for vision and lens fit assessments and will complete surveys about their wear experience.


Eligibility criteria:
inclusion criteria: 1. at least 18 years of age 2. ability to give informed consent 3. current acuvue® oasys® spherical lens wearer. 4. distance visual acuity of 20/25 or better with current contact lenses in each eye. 5. good general health defined by, medication use that has not changed within the last 30 days and the absence of medical conditions or treatments that are deemed confounding to the data as determined by the investigator. 6. willing to spend time for the study, which includes: attend three study visits and wear contact lenses on days between study visits. exclusion criteria: 1. current or active ocular inflammation or infection as determined by the investigator. 2. currently pregnant or lactating. (participants will be asked to self-report these conditions). 3. systemic inflammatory disease (i.e. diabetes, etc.) that could confound study results in the opinion of the investigator.

Keywords: contact lenses
the effect of weight bearing status on healing and pain outcomes after surgery for osteochondral defects of the ankle

Conditions: Osteochondritis Dissecans of Ankle and Joints of Foot

Summary: the rationale for this research study is to evaluate the effect on clinical outcomes of weight bearing as tolerated after forage surgery for the treatment of osteochondral defects of the ankle, thus potentially eliminating the need for a period of immobilisation or non-weight bearing after surgery. the investigators hypothesize that their will be no difference in functional outcomes between weight bearing as tolerated as compared to non-weight bearing for six weeks after forage surgery for ocd of the ankle.

the hypothesis for advantage of the investigational post-operative therapy is based on: equivalent clinical outcomes to non-weight bearing; similar radiographic findings on ct at follow-up visit between the two groups; reduced morbidity and disability to subjects through elimination of a period of non-weight bearing; reduction of cost to patients by eliminating need for adjuvant walking and mobility aids (crutches, taxis) and time off work.

Eligibility criteria:
inclusion criteria: * patients aged 16-60 years * no prior ankle surgery * able and willing to comply with follow-up * capable of provide informed consent * medically fit for surgery * lesions on preoperative ct scan \< 1.5cm * symptomatic (ie:pain, restricted activities, inability to wb, decreased rom) * single isolated lesion * failure of conservative treatment (3 months of limited activities and/or weight bearing and/or immobilization) exclusion criteria: age less than 16 years or greater than 60 years * inflammatory arthritis * diffuse osteoarthritis of affected joint * associated fracture * prior ankle surgery for current injury (including arthroscopy) * unable to comply with follow-up * unable to provide informed consent * bernt \& hardy class iv (amenable to orif) * multiple osteochondral defects in one ankle or touching osteochondral lesions of tibia and talus * prior osteochondral defects of the affected ankle
cardiovascular risks and urinary albumin excretion(uae) in polycystic ovarian syndrome (pco)

Conditions: Urinary Albumin Excretion

Summary: pco patients will be assessed clinically,urine \& blood samples will be tested. systolic \& diastolic blood pressure, serum glucose \& insulin levels, lipid profile, c-reactive protein, complete hormonal profile, and urinary albumin excretion will be measured.

pco patients with 2 of 3 criteria: oligo- or anovulation ; hyperandrogenism \&polycystic ovaries. exclusion criteria: pregnancy, diabetes, hypertension , adrenal \& thyroid dysfunction. blood samples after overnight fast (8hrs) at day 2 or 3 of menstrual cycle. serum concentration of follicle stimulating hormone (fsh), luteinizing hormone (lh), prolactin, total testosterone \& sex hormone binding globulin, serum 17-hydroxy (oh) progesterone \& dehydroepiandrosterone sulfate will be measured. oral glucose tolerance test \& plasma insulin levels will be measured. total cholesterol, triglycerides, high\& low density lipoproteins. urinary albumin will be measured\& all the data will be analysed.

Eligibility criteria:
inclusion criteria: * pco patients exclusion criteria: * pregnancy * diabetes * hypertension * adrenal dysfunction * thyroid dysfunction
study of anti-cd19/cd22 car nk cells in relapsed and refractory b cell lymphoma

Conditions: Refractory B-Cell Lymphoma

Summary: this is a single-centre, single-arm and open-label study to investigate the safety and efficacy of anti cd19/cd22 car nk cells in patients with relapsed refractory b cell lymphoma.


Eligibility criteria:
inclusion criteria: 1. cd19(+) cd22(+) b cell lymphoma confirmed by pathological immunohistochemistry or flow cytometry 2. previously accepted ≥ first-line regimen chemotherapy 3. unconditional acceptance of hematopoietic stem cell transplantation or recurrence after hematopoietic stem cell transplantation 4. over 18 years old and under 70 years old 5. the expected survival period is more than 3 months. 6. ecog≤2 7. important organ function is satisfied: cardiac ultrasound indicates cardiac ejection fraction ≥50%, no abnormal electrocardiogram; blood oxygen saturation ≥90%; creatinine clearance ≥40 ml/min; alt and ast≤3 times normal range, total bilirubin ≤ 2.0 mg / dl; 8. blood routine: hgb≥80 g/l, anc≥1×109/l, plt≥50×109/l; 9. the pregnancy test for women of childbearing age must be negative; both men and women must agree to use effective contraception during the treatment period and for the following 1 year. 10. measurable target lesion exclusion criteria: 1. patients with extramedullary relapse 2. burkitt's lymphoma/leukemia 3. previously received gene product treatment, anti-cd19/anti-cd3 treatment, or any anti-cd19/cd22 treatment; 4. liver and kidney function: * total bilirubin \> 2 x uln (gilbert syndrome \> 3 x uln) * aspartate aminotransferase (ast) and alanine aminotransferase (alt) \> 3 × uln * serum creatinine clearance \>60 ml/min 5. serological examination: * absolute neutrophil count (anc) \<0.75x109/l * platelet count (plt) \<50x109/l 6. active hepatitis b (hbv-dna \> 1000 copies / ml), hepatitis c, or uncontrolled infection 7. gvhd ≥ 2 or anti-gvhd treatment 8. im19 car nk cells received allogeneic cell therapy within 6 weeks before infusion, such as donor lymphocyte infusion; 9. subject received the most recent treatment (release, chemotherapy, or other) less than 4 weeks 10. active cns disease (tumor cells in csf, but \< 5 wbcs/ml can be included); 11. intracranial hypertension or unconsciousness; respiratory failure; diffuse vascular internal coagulation 12. creatinine \> 1.5 times normal upper limit or alt / ast \> 3 times normal upper limit or bilirubin \> 2 times normal upper limit 13. new york heart association (nyha) graded above or above 14. uncontrollable diabetes 15. suffering from other uncontrolled diseases, the researchers believe that it is not suitable for joining 16. any situation that the investigator believes may increase the risk of the subject or interfere with the test results
effects of ezetimibe, simvastatin, and vytorin on reducing l5 a subfraction of ldl in patients with metabolic syndrome.

Conditions: Metabolic Syndrome

Summary: the purpose of this study is: * to identify the common factor for l5 prevalence in patients with metabolic syndrome. * to determine whether ezetimibe, simvastatin, and vytorin can correct the l5- promoting factor and reduce l5 in metabolic syndrome patients.

epidemiological evidence indicates that metabolic syndrome (ms) is a strong predisposing condition for atherosclerosis. elevation of plasma low-density lipoprotein (ldl) cholesterol(ldl-c) concentration is the most important risk factor for atherosclerosis; however, ldl-c elevation is not a criterion for metabolic syndrome, raising the question of ldl's role in the syndrome's association with atherosclerosis. l5, a highly electronegative and mildly oxidized ldl subfraction that we recently isolated from hypercholesterolemic human plasma, may provide a key to answering this question. in cultured vascular endothelial cells (ec), l5 inhibits proliferation and induces apoptosis and monocyte-ec adhesion. in our preliminary studies, l5 could also be detected in patients with ms without elevated ldl-c. because other ldl subfractions were harmless to ec, the presence of ms-l5 prompted us to hypothesize that the atherogenic role of ldl is not solely determined by plasma ldl-c concentration, but more importantly, by its composition. the proposed study is designed to test this hypothesis. the first question we will address is what lipid factor determines the prevalence of l5 in ms. subsequently, we will examine whether treatment with selected medicines can effectively reduce l5 in ms patients by correcting the factor favorable for l5 formation. we are in the process of identifying the active components of l5 to fully characterize the atherogenic role of l5 in ms,. in the current proposal, we focus our interest on the efficacy of ezetimibe, simvastatin, and vytorin in reducing l5 from the plasma of ms patients.

Eligibility criteria:
inclusion criteria: * participants who meet 3 or more of the 5 criteria specified in the atpiii guidelines will be recruited. * the 5 criteria are: 1. abdominal obesity (men\>40 inches, women \>35 inches); 2. tg\> 150mg/dl; 3. low hdl-c (men \< 40mg/dl, women \< 50 mg/dl); 4. high blood pressure (\>or=130/\>or=85 mmhg); 5. fasting glucose \> or = 110mg/dl. * people with different ethnic backgrounds will be included. exclusion criteria: * symptomatic coronary artery disease * peripheral vascular disease * cerebral ischemia (stroke) * smoking * hypothyroidism * kidney diseases * consumption of antioxidation supplements/drugs or use of lipid-lowering drugs in the last 3 months * women who are pregnant, nursing, or planning to become pregnant

Keywords: metabolic syndrome ldl subfraction l5 the reduction of ldl in patients with metabolic syndrome the prevalence of l5 in patients with metabolic syndrome the reduction of l5 in patients with metabolic syndrome
the impact of music on nociceptive processing

Conditions: Pain, Acute; Pain, Chronic; Anxiety; Anxiety Disorders; Catastrophization; Healthy

Summary: the investigators are studying the ways that different music may change pain perception

in this study, the investigators are comparing healthy individuals to hiv and fibromyalgia patients. the investigators are measuring the differences in pain processing between subject groups in the presence and absence of different music and distraction conditions. the investigators will be using quantitative sensory testing (qst) in order to induce varying pain conditions on the participants. the investigators will also have participants complete sets of psychosocial questionnaires. patients with fibromyalgia tend to have a higher pain sensitivity. additionally, patients with an hiv diagnosis tend to be prescribed opioid medications. the investigators would like to find out if music can modulate pain, and in turn help reduce the amount of opioid medications those with a chronic pain diagnosis take.

Eligibility criteria:
healthy volunteers no longer needed for this study (9/9/2021). inclusion criteria for healthy volunteers (n=70) without a diagnosis of neuropathy or chronic pain: * aged \>18 years * able to speak and understand english * willingness to undergo psychophysical and psychosocial testing. exclusion criteria: * diagnosed hearing loss * diagnosis of chronic pain/neuropathy * history of chronic opioid use (having an opioid prescription \>30 days). inclusion criteria for fibromyalgia patients: n=70: * aged \>18 years * have a diagnosis of fibromyalgia with concurrent chronic pain for \> 6 months, and meet the wolfe et al 2011 research criteria for fibromyalgia * have an average self-reported pain score of 4/10 or greater * willing to undergo psychophysical and psychosocial testing * able to speak and understand english. exclusion criteria: --diagnosed hearing loss. hiv patients with chronic pain: n=70 * aged \>18- years * have a diagnosis of hiv infection * have had chronic pain with onset \> 6 months * have an average self-reported pain score of 4/10 or greater * willing to undergo psychophysical and psychosocial testing * able speak and understand english. exclusion criteria: --diagnosed hearing loss.

Keywords: music
succinylcholine or rocuronium for rigid bronchoscopy under general anesthesia

Conditions: Anesthesia

Summary: myorelaxation is generally used as a part of general anesthesia for interventional rigid bronchoscopy. succinylcholine is most often used because its short duration of action but rocuronium can be used since sugammadex permits a rapid and complete reversal of the neuromuscular block. the aim of ths study is to compare both agents.


Eligibility criteria:
inclusion criteria: * patients scheduled for an interventional rigid bronchoscopy under general anesthesia exclusion criteria: * pregnant woman or woman of childbearing age, * morbid obesity, * drug allergy,contra-indication to succinylcholine, rocuronium, sugammadex, propofol, remifentanil, * history of central neurological or brain damage, * psychotropic treatment, * pacemaker, * renal failure, * disease of the neuromuscular junction.
usability and effectiveness of the atlas2030 exoskeleton in children with cerebral palsy

Conditions: Cerebral Palsy

Summary: the main objective of this study is to assess the usability and efficacy of receiving therapy with the peaditric exoskeleton atlas 2030in children with gait impairment due to a cerebral palsy condition. it will be valued the impact of rehabilitation with the exoskeleton at the physical level on parameters such as joint range, spasticity, as well as the impact in quality of life. it is also assessed the impact at the level of functionality of the participants, through the administration of different functional assessment scales.


Eligibility criteria:
inclusion criteria: * medical authorization to for standing, gait training and weight bearing. * maximum user weight of 35 kg. * length of the thigh (distance from the greater trochanter to the lateral condyle of the tibia) from 24cm to 33cm. * tibia leg length (distance from the lateral condyle of the tibia to the lateral malleolus) from 23cm to 32cm. * hip width (between greater trochanteres) less than or equal to 35 cm. * do not have an allergy to any of the atlas materials: cotton, nylon, polyester, polyamide, polyethylene or propylene. * ability to achieve the neutral position of the ankle, during the use of the device with or without technical aids. * informed consent signed by legal guardians. * confirmed diagnosis of cerebral palsy affecting the ability to walk. * stable medical condition without modifications of the specific medication for the disease in the last 6 months, and other additional medication in the last month. * patient in follow-up according to the normal standards recommended for his illness. exclusion criteria: * more than 20º of hip flessum at the time of using the exoskeleton. * more than 20º of knee flessum at the time of using the exoskeleton. * severe skin lesion on parts of the lower extremities that are in contact with the device. * scheduled surgery (rachis, limbs) for the duration of the study or surgery performed (rachis, extremities) in the last 6 months. * history of fracture without trauma. history of bone fracture traumatic in lower extremities or pelvic girdle in the last 3 months. * refusal of the patient or legal guardian to include the child in the study. * skin problems (diseases, allergies, sensitivity ...) that prevent the use of exoskeleton accessories on the patient's skin. * spasticity equal to 4 on the modified ashworth scale at the time of use of the device.

Keywords: exoskeleton paediatric gait robotic gait assited training